Innovation 

Contact list for managers in the Innovation Division

A Discussion Paper on the Intermediary Access program for public consultation

The following report was prepared for the Department of Industry, Tourism and Resources by Professor Ron Johnston, Executive Director of the Centre for Innovation (ACIIC). It outlines the key issues, drivers and uncertainties for the future of the Australian medical devices industry, and provide major initiatives that the industry can take to grow and remain internationally competitive to the year 2025.

Describes the work of the National Nanotechnology Strategy Taskforce in developing options for a coordinated national nanotechnology strategy.

Information on the Innovation Investment Fund

Links to websites within the Department and to other federal and state and territory government agencies involved in innovation policy.

Innovation is a major driver of commercial and economic growth and Intellectual Property (IP) protection is an essential requirement for pharmaceutical companies to be able to fund investment in research and development.

Information on the new 5 year Intermediary Access Program

Submission to the Nanotechnology Strategy Taskforce in 2006 by Nanovic (Nanotechnology Victoria Ltd)

This is the Executive Summary for the Options for a National Nanotechnology Strategy Report.

Information on the Pre-Seed fund

Information about the Prime Minister's Science, Engineering and Innovation Council (PMSEIC) and

Information on the ICIP

Information about a one-off A$10 million grant to support the establishment of a small-scale mammalian cell production facility in Australia to bridge the infrastructure gap in the national biotechnology manufacturing value chain.

Fact Sheet relating to a one-off A$10 million grant to support the establishment of a small-scale mammalian cell production facility in Australia.

Sample funding agreement relating to a one-off A$10 million grant to support the establishment of a small-scale mammalian cell production facility in Australia.

Guidelines to assist applicants in applying for a one-off A$10 million grant to support the establishment of a small-scale mammalian cell production facility in Australia.

In addition to the $1 billion over five years announced in 2004 for Commercial Ready, the Australian Government has allocated $90.3 million over ten years to Commercial Ready Plus for emerging companies and spin offs from public research organisations.

Innovation seminar run by the Innovation Division, featuring Don Soctt-Kemmis

A free public forum to assist members of the public gain a better understanding of nanotechnology and to encourage community dialogue about issues concerning nanotechnology will be held in Sydney on Thursday, 3 April.

A free public forum to discuss issues about nanotechnology will be held at Adelaide University on the evening of Thursday, 8 May, providing an opportunity to hear varying expert opinions and ask questions.

A free public forum to discuss issues about nanotechnology will be held at the Old Woolstore Apartment Hotel in Hobart on the evening of Tuesday 3 June, providing an opportunity to hear varying expert opinions and to ask questions about nanotechnology.

A free public forum at the University of Western Australia on Wednesday 18 June will provide an opportunity for people to hear a variety of expert opinions and to ask questions about nanotechnology.

Dr Terry Cutler, the head of the Government's independent review of Australia's National Innovation System says he is delighted, but daunted, by the number and variety of submissions made to the Review.

One area of great interest is biotechnology. Already biotechnology is having a marked impact on how we live, in producing new medicines, helping solve environmental problems and providing fuel and food for the future.

This presentation was given by Craig Pennifold, Head of Innovation Division, Department of Industry, Tourism and Resources at the 5th Annual Biotech Summit in August 2007

Part of a series of occasional papers to encourage debate on issues relating to emerging industries and technologies.

A preliminary study into the Australian Complementary Medicines Industry

'Behavioural Additionality' is a new approach to determining the effectiveness of government R&D funding.

Biotech Business Indicators provides a quarterly updated ready reference to biotechnology industry and market developments, using key industry and market statistics.

Biotech Business Indicators provides a ready reference to biotechnology industry and market developments, using key industry and market statistics.

Biotech Business Indicators provides a ready reference to biotechnology industry and market developments, using key industry and market statistics.

Biotech Business Indicators provides a quarterly updated ready reference to biotechnology industry and market developments, using key industry and market statistics.

Biotech Business Indicators provides a quarterly updated ready reference to biotechnology industry and market developments, using key industry and market statistics.

Biotech Business Indicators provides a quarterly updated ready reference to biotechnology industry and market developments, using key industry and market statistics.

Boost your Business with Biotech - Hazardous Waste Management flyer and further information

A survey of business angel investors and networks in Australia

Report on the level of IP protection used by SMEs in Australia, undertaken by the Intellectual Property Research Institute of Australia

A survey investigating behavioural additionality effects of the R&D Tax Concession program.

The Australian Government's Industrial Biotechnology strategy highlights the benefits that industrial biotechnology can offer Australian industry and highlights strategy initiatives for 2007-08.

A report on the views of investors, and companies that have not participated in the COMET program, on potential gaps in levels of finance available for commercialisation activities.

A summary of the 2005 report on the impact that the Commercialising Emerging Technologies (COMET) program has on participating firms in terms of developing knowledge-based skills and innovation capability.

A Business Case study for an Australian Mammalian Cell Biopharmaceutical Facility.

The Report was launched on 26 July 2006 and details the thirteen recommendations to be implemented by industry to achieve the industry's vision

The Executive summary of the Medical Devices Industry Action Agenda Report containing thirteen recommendations to help the industry grow.

A 2007 survey to gauge community understanding of nanotechnology.

A study of business' understanding of and attitudes towards nanotechnology.

A 2006 Nanotechnology business survey report to gauge the level of awareness and understanding of nanotechnology issues among targeted firms with a potential interest in nanotechnology.

This report outlines the results of a survey of n=105 businesses commissioned by NanoVic and the Australian Government Department of Industry, Tourism and Resources (DITR) to establish current investment in and attitudes towards nanotechnology and to identify potential barriers to investing in the emerging science. The survey sample was drawn from the manufacturing, materials, automotive, ICT/ electronics, textiles, and biotechnology industries.

This is the options report for a National Nanotechnology Strategy prepared by the National Nanotechnology Strategy Taskforce. June 2006.

A 2005 survey of Patenting and Commercialisation activities of Australian Universitites from 1995 to 2002.

Recent reports concerning aspects of the R&D Tax Concession

This report is written to raise awareness in the wider business and investor community about nanotechnology, its applications and opportunites

A report of a study undertaken to assess the role of and benefits created by intermediaries in the Australian innovation system.

A study of the impact of the Australian Government's R&D tax Concession on 116 firms that are current or past participants in the program.

This report, produced in July 2004, looks at the role of business plan competitions in the innovation cycle.

The annual ABS survey on Australian Venture Capital and Private Equity

The Department collaborated with the ABS to produce a detailed, policy relevant analysis of the data collected in the 2003 Innovation Survey.

A data card summary of business research and development expenditure in Australia over time, and by industry sector.

This paper builds on previous innovation analysis by DITR and the ABS. It presents the results of an econometric investigation into innovation novelty, collaboration and related characteristics in Australian business.

A study on the sources of investment for COMET companies

The DITR "Innovation in Manufacturing 2003" paper presents an analysis of innovation in Australian manufacturing in 2001-2003 using micro-level data from the ABS's 2003 Innovation Survey.

A comparison of Intellectual Property protection activity in Australia, the USA, and the EU in 2000-2004

A comparison of Intellectual Property protection activity in Australia, the USA, and the EU in 2000-2004 in A3 downloadable format

A comparison of Intellectual Property protection activity in Australia, the USA, and the EU in 2000-2004 in A4 downloadable format

The research study provides an overview of the main patterns of innovation in Australian businesses, the general characteristics of innovators and an analysis of expenditure on innovation.

A summary report on early stage venture capital investments in Australia.

The Knowledge Intensive Service Activities (KISA) study was an OECD project which focussed on developing an understanding of how firms in different industries use KISA in their innovation processes to develop knowledge based skills and capabilities.

A study of a small number of selected participants in the R&D Start and Biotechnology Innovation Fund programs.

A page to house national nanotechnology strategy implementation plan file.

Summary of nanotechnology related surveys undertaken by or for the Department since October 2004

A 2007 survey of six Australian Phase 1 clinical trials units.